Skip to main content
Log in

Septische Arthritis und Spondylodiszitis

Selten, aber gefürchtet

Septic arthritis and spondylodiscitis

Rare but feared diseases

  • Infektiologie
  • Published:
rheuma plus Aims and scope

Zusammenfassung

Die septische Arthritis und Spondylodiszitis sind eher seltene, aber gefährliche Infektionen mit zunehmender Inzidenz. Die septische Arthritis stellt eine Notfallerkrankung dar, die von einer hohen Morbidität (40 %) und einer nicht unerheblichen Letalität (11 %) gekennzeichnet ist. Die Infektion des Gelenkes entsteht entweder hämatogen, durch direkte Inokulation oder per continuitatem. Patienten mit vorbestehenden Gelenkdestruktionen oder Immunsuppression sind besonders gefährdet. Vor Einleiten der Antibiotikatherapie sollte über die Asservation der Synovialflüssigkeit eine Erregersicherung und Leukozytenquantifizierung erfolgen. Zum Gelenkerhalt ist eine frühzeitige Evakuation der infizierten Synovia aus dem Gelenk unerlässlich. Die Spondylodiszitis beschreibt eine Infektion der Bandscheibe und angrenzenden Wirbelkörper, die v. a. durch hämatogene Dissemination entsteht. Insbesondere immunsupprimierte und ältere Menschen sind gefährdet für diese Infektion. Die Diagnosestellung ist häufig verspätet, da das führende Symptom, der Rückenschmerz, sehr unspezifisch ist und Fieber in weniger als der Hälfte der Fälle auftritt. In Europa ist Staphylococcus aureus der häufigste Erreger, während weltweit die Tuberkulose führend ist. Bildgebend ist die Magnetresonanztomographie das Verfahren der Wahl. Bei stabilen Patienten sollte zuerst die Erregerisolierung (Blutkulturen oder Gewebeproben mittels Computertomographie-gesteuerter Punktion oder offener Biopsie) vor Beginn der antimikrobiellen Therapie erfolgen. Die empfohlene Dauer der erregerspezifischen antibiotischen Therapie beträgt bei nativer Spondylodiszitis in der Regel 6 Wochen.

Abstract

Septic arthritis and spondylodiscitis are relatively rare but severe diseases with increasing incidence. Septic arthritis is an emergency situation with high morbidity (40 %) and fatality rates (11 %). The infection occurs via a hematogenous route by direct inoculation or per continuitatem. Patients with pre-existing destructive joint diseases or under immunosuppressive treatment are particularly at risk. It is mandatory to sample synovial fluid for isolation of the relevant pathogen and quantification of leucocytes before starting antibiotic therapy. In order to preserve the joint, early evacuation of the infected synovial space is necessary. Spondylodiscitis is characterized by infection of the vertebra and neighboring discs mainly via a hematogenous route. Immunosuppressed and older patients are primarily at risk of infection. Back pain represents the main symptom but due to its unspecific character and the frequent absence of fever, diagnosis is often delayed. In Europe Staphylococcus aureus is the most prevalent pathogen, whereas tuberculosis is the most frequent causal agent worldwide. Magnetic resonance imaging (MRI) respresents the method of choice for the radiological diagnostics. In stable patients isolation of the pathogen should be achieved before starting antimicrobial therapy (e.g. blood cultures or tissue samples by computed tomography guided puncture or biopsy). The recommended duration of pathogen-specific antibiotic therapy for native spondylodiscitis is normally 6 weeks.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Abb. 1
Abb. 2

Literatur

  1. Kaandorp CJ, Van Schaardenburg D, Krijnen P, Habbema JD, van de Laar MA (1995) Risk factors for septic arthritis in patients with joint disease. A prospective study. Arthritis Rheum 38(12):1819–1825

    Article  CAS  PubMed  Google Scholar 

  2. Garcia-Arias M, Balsa A, Mola EM (2011) Septic arthritis. Best Pract Res Clin Rheumatol 25(3):407–421. doi:10.1016/j.berh.2011.02.001

    Article  PubMed  Google Scholar 

  3. Weston VC, Jones AC, Bradbury N, Fawthrop F, Doherty M (1999) Clinical features and outcome of septic arthritis in a single UK Health District 1982–1991. Ann Rheum Dis 58(4):214–219

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Kaandorp CJ, Dinant HJ, van de Laar MA, Moens HJ, Prins AP, Dijkmans BA (1997) Incidence and sources of native and prosthetic joint infection: A community based prospective survey. Ann Rheum Dis 56(8):470–475

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Gupta MN, Sturrock RD, Field M (2001) A prospective 2‑year study of 75 patients with adult-onset septic arthritis. Rheumatology (Oxford) 40(1):24–30

    Article  CAS  Google Scholar 

  6. Rozadilla A, Nolla JM, Mateo L, del Blanco J, Valverde J, Roig D (1992) Septic arthritis induced by pyogenic germs in patients without parenteral drug addiction. Analysis of 44 cases. Med Clin (Barc) 98(14):527–530

    CAS  Google Scholar 

  7. Mathews CJ, Weston VC, Jones A, Field M, Coakley G (2010) Bacterial septic arthritis in adults. Lancet 375(9717):846–855. doi:10.1016/S0140-6736(09)61595-6

    Article  PubMed  Google Scholar 

  8. Shirtliff ME, Mader JT (2002) Acute septic arthritis. Clin Microbiol Rev 15(4):527–544

    Article  PubMed  PubMed Central  Google Scholar 

  9. Landewe RB, Gunther KP, Lukas C, Braun J, Combe B (2010) Conaghan PG et al EULAR/EFORT recommendations for the diagnosis and initial management of patients with acute or recent onset swelling of the knee. Ann Rheum Dis 69(1):12–19. doi:10.1136/ard.2008.104406

    Article  CAS  PubMed  Google Scholar 

  10. Jung N, Koop H, Riessen R, Galle JC, Jany B, Marker-Herrmann E (2016) “Choosing wisely” in infectious diseases: Overuse of antibiotics – too few vaccinations. Internist. doi:10.1007/s00108-016-0063-5

    Google Scholar 

  11. Dubost JJ, Soubrier M, De Champs C, Ristori JM, Bussiere JL, Sauvezie B (2002) No changes in the distribution of organisms responsible for septic arthritis over a 20 year period. Ann Rheum Dis 61(3):267–269

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Zimmerli W, Trampuz A, Ochsner PE (2004) Prosthetic-joint infections. N Engl J Med 351(16):1645–1654. doi:10.1056/NEJMra040181

    Article  CAS  PubMed  Google Scholar 

  13. Dubost JJ, Fis I, Denis P, Lopitaux R, Soubrier M, Ristori JM et al (1993) Polyarticular septic arthritis. Medicine (Baltimore) 72(5):296–310

    Article  CAS  Google Scholar 

  14. Coutlakis PJ, Roberts WN, Wise CM (2002) Another look at synovial fluid leukocytosis and infection. J Clin Rheumatol 8(2):67–71

    Article  PubMed  Google Scholar 

  15. Coakley G, Mathews C, Field M, Jones A, Kingsley G, Walker D et al (2006) BSR & BHPR, BOA, RCGP and BSAC guidelines for management of the hot swollen joint in adults. Rheumatology (Oxford) 45(8):1039–1041. doi:10.1093/rheumatology/kel163a

    Article  CAS  Google Scholar 

  16. Smith JW, Chalupa P, Shabaz HM (2006) Infectious arthritis: Clinical features, laboratory findings and treatment. Clin Microbiol Infect 12(4):309–314. doi:10.1111/j.1469-0691.2006.01366.x

    Article  CAS  PubMed  Google Scholar 

  17. Sharff KA, Richards EP, Townes JM (2013) Clinical management of septic arthritis. Curr Rheumatol Rep 15(6):332. doi:10.1007/s11926-013-0332-4

    Article  PubMed  Google Scholar 

  18. Zimmerli W (2010) Clinical practice. Vertebral osteomyelitis. N Engl J Med 362(11):1022–1029

    Article  CAS  PubMed  Google Scholar 

  19. Mylona E, Samarkos M, Kakalou E, Fanourgiakis P, Skoutelis A (2009) Pyogenic vertebral osteomyelitis: A systematic review of clinical characteristics. Semin Arthritis Rheum 39(1):10–17

    Article  CAS  PubMed  Google Scholar 

  20. Kehrer M, Pedersen C, Jensen TG, Hallas J, Lassen AT (2015) Increased short- and long-term mortality among patients with infectious spondylodiscitis compared with a reference population. Spine J 15(6):1233–1240. doi:10.1016/j.spinee.2015.02.021

    Article  PubMed  Google Scholar 

  21. Kehrer M, Pedersen C, Jensen TG, Lassen AT (2014) Increasing incidence of pyogenic spondylodiscitis: A 14-year population-based study. J Infect 68(4):313–320. doi:10.1016/j.jinf.2013.11.011

    Article  PubMed  Google Scholar 

  22. Eren Gok S, Kaptanoglu E, Celikbas A, Ergonul O, Baykam N, Eroglu M et al (2014) Vertebral osteomyelitis: clinical features and diagnosis. Clin Microbiol Infect 20(10):1055–1060. doi:10.1111/1469-0691.12653

    Article  CAS  PubMed  Google Scholar 

  23. Pigrau C, Almirante B, Flores X, Falco V, Rodriguez D, Gasser I et al (2005) Spontaneous pyogenic vertebral osteomyelitis and endocarditis: Incidence, risk factors, and outcome. Am J Med 118(11):1287. doi:10.1016/j.amjmed.2005.02.027

    Article  PubMed  Google Scholar 

  24. Koslow M, Kuperstein R, Eshed I, Perelman M, Maor E, Sidi Y (2014) The unique clinical features and outcome of infectious endocarditis and vertebral osteomyelitis co-infection. Am J Med 127(7):669 e9–669 e15. doi:10.1016/j.amjmed.2014.02.023

    Article  Google Scholar 

  25. Palestro CJ, Love C, Miller TT (2006) Infection and musculoskeletal conditions: Imaging of musculoskeletal infections. Best Pract Res Clin Rheumatol 20(6):1197–1218. doi:10.1016/j.berh.2006.08.009

    Article  PubMed  Google Scholar 

  26. Jung N, Seifert H, Siewe J, Fatkenheuer G (2013) Vertebral osteomyelitis. Internist (Berl) 54(8):945–953. doi:10.1007/s00108-012-3142-2

    Article  CAS  Google Scholar 

  27. Berbari EF, Kanj SS, Kowalski TJ, Darouiche RO, Widmer AF, Schmitt SK et al (2015) Infectious Diseases Society of America (IDSA) clinical practice guidelines for the diagnosis and treatment of native vertebral osteomyelitis in adults. Clin Infect Dis 61(6):e26–e46. doi:10.1093/cid/civ482

    Article  PubMed  Google Scholar 

  28. Zarghooni K, Rollinghoff M, Sobottke R, Eysel P (2012) Treatment of spondylodiscitis. Int Orthop 36(2):405–411

    Article  PubMed  Google Scholar 

  29. Bernard L, Dinh A, Ghout I, Simo D, Zeller V, Issartel B et al (2015) Antibiotic treatment for 6 weeks versus 12 weeks in patients with pyogenic vertebral osteomyelitis: An open-label, non-inferiority, randomised, controlled trial. Lancet 385(9971):875–882. doi:10.1016/S0140-6736(14)61233-2

    Article  CAS  PubMed  Google Scholar 

  30. Park KH, Cho OH, Lee JH, Park JS, Ryu KN, Park SY et al (2016) Optimal duration of antibiotic therapy in patients with hematogenous vertebral osteomyelitis at low risk and high risk of recurrence. Clin Infect Dis 62(10):1262–1269. doi:10.1093/cid/ciw098

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to N. Jung.

Ethics declarations

Interessenkonflikt

S. Vossen gibt an, dass kein Interessenkonflikt besteht. N. Jung gibt an, Vortragshonorare von Labor Stein, Novartis, Astellas Pharma, Alere GmbH, Basilea Pharmaceutica AG, Reiseunterstützung von Astellas, Novartis und Gilead sowie Honorare für eine Beobachtungsstudie von Infectofos erhalten zu haben.

Dieser Beitrag beinhaltet keine von den Autoren durchgeführten Studien an Menschen oder Tieren.

Additional information

Erstveröffentlichung in Zeitschrift für Rheumatologie (online am 15. September 2016). doi:10.1007/s00393-016-0200-5.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Jung, N., Vossen, S. Septische Arthritis und Spondylodiszitis. rheuma plus 16, 24–30 (2017). https://doi.org/10.1007/s12688-016-0092-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12688-016-0092-0

Schlüsselwörter

Keywords

Navigation